The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia

Clinical Pharmacokinetics
S UlrichF P Meyer

Abstract

Haloperidol is the most commonly used antipsychotic drug in the therapy of acute schizophrenia. Clinicians have been using therapeutic drug monitoring in an attempt to improve clinical application of this drug. The scale of interest in this area is emphasised by the large number of studies (about 50) concerning the serum concentration-therapeutic effect relationship (SCTER) of haloperidol, including 35 studies on patients with acute schizophrenia. However, conflicting results concerning the existence and position of a therapeutic window have emerged. This article aims to provide a comprehensive review of the study design of studies in patients with acute schizophrenia before the study data are used for decision-making. For this purpose, a reproducible system for the evaluation of studies in this special area, a so-called total study score (TSS), was developed on an empirical basis. Thus, insufficient study design was found to be a reason for negative results. On the other hand, in spite of a great variability, the majority of studies with good design provided evidence for a significant SCTER: a bisigmoidal dependence of clinical effect on haloperidol serum concentration. The therapeutic effects of haloperidol increase at low co...Continue Reading

Citations

Feb 21, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norio Yasui-FurukoriKoichi Otani
Sep 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tsuyoshi KondoSunao Kaneko
Sep 8, 2000·Clinical Pharmacokinetics·J A Carrillo, J Benitez
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Feb 18, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alexandra KaufmannAlex Hofer
Oct 1, 2005·Nordic Journal of Psychiatry·Ragnar Nesvåg, Lars Tanum
Mar 16, 2011·Expert Opinion on Drug Metabolism & Toxicology·Silvio CacciaMaurizio Bonati
Mar 17, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tetsuhito MurataYuji Wada
Mar 3, 2007·The Journal of Pharmacy and Pharmacology·Koichi IwakiKatsuhiko Okumura
Mar 30, 2016·Pharmacogenomics·Stefano PorcelliDan Rujescu
Sep 21, 2013·Schizophrenia Research·Rodolfo BongiovanniGeorge E Jaskiw
Sep 19, 2006·The International Journal of Neuropsychopharmacology·Tetsuhito MurataYuji Wada
Oct 27, 2017·Acta Psychiatrica Scandinavica·R McCutcheonO D Howes
Sep 2, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Eveline Jaquenoud SirotPierre Baumann
Jan 16, 2008·European Journal of Clinical Pharmacology·Christoph Hiemke
Dec 29, 2000·Therapeutic Drug Monitoring·S Kruggel, S Ulrich
Mar 27, 2003·Therapeutic Drug Monitoring·John F Wilson
May 19, 2020·Expert Opinion on Drug Safety·Sanne M KloosterboerBirgit C P Koch
Dec 29, 2020·Frontiers in Genetics·Beatriz Carvalho HenriquesKatherine J Aitchison
Feb 24, 2001·Journal of Chromatography. a·S Ulrich
Aug 15, 2021·Neuropsychopharmacology Reports·UNKNOWN Japanese Society of Neuropsychopharmacology
Dec 14, 2021·Frontiers in Psychiatry·Xenia M HartGerhard Gründer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here